Blog
RSS FeedPosted by Michael Wonder on 01 Mar 2021
Dapagliflozin in chronic heart failure: hint of added benefit
1 March 2021 - Diabetes drug is also effective in symptomatic chronic heart failure with reduced pump function. However, the additional ...
Posted by Michael Wonder on 22 Feb 2021
Clinical relevance of patient-reported outcomes: new threshold proves to be practical
18 February 2021 - Current examples show that the 15% threshold newly set by IQWiG for the recognition of responder analyses ...
Posted by Michael Wonder on 04 Jan 2021
Ibrutinib with rituximab in previously untreated chronic lymphocytic leukaemia: indication of added benefit over FCR
4 January 2020 - The new drug combination prolongs overall survival in patients in good general health. No study data are ...
Posted by Michael Wonder on 13 Dec 2020
Qualitative comparative analysis of health economic evaluation guidelines for health technology assessment in European countries
10 December 2020 - Zisis and colleagues performed a literature review to identify published guidance for the conduct and assessment ...
Posted by Michael Wonder on 03 Dec 2020
Secukinumab in children with plaque psoriasis: study unsuitable for benefit assessment
3 December 2020 - Inappropriate treatment in the control arm makes fair comparison impossible. ...
Posted by Michael Wonder on 02 Dec 2020
IQWiG publishes 1,000th report
2 December 2020 - In the 16th year of its existence, IQWiG has published its 1,000th report: a dossier assessment ...
Posted by Michael Wonder on 19 Nov 2020
Trifarotene in moderate acne: no study data for the assessment of the added benefit
16 November 2020 - Only studies with placebo comparisons despite many affected people and existing treatment alternatives. ...
Posted by Michael Wonder on 05 Nov 2020
IQWiG publishes a new version of its general methods
5 November 2020 - New features include the investigation of volume-outcome relationships and different mean observation times in clinical studies. ...
Posted by Michael Wonder on 01 Oct 2020
Fostamatinib in chronic immune thrombocytopenia: added benefit not proven due to lack of comparison
1 October 2020 - Only placebo controlled studies in the dossier. ...
Posted by Michael Wonder on 29 Sep 2020
Germany has not fully realised its biosimilar potential
29 September 2020 - Investigators have concluded that fully realizing the cost-saving potential of biosimilars could “release enormous resources” for ...
Posted by Michael Wonder on 21 Sep 2020
Second joint meeting on ‘Innovations in Healthcare’
18 September 2020 - How can methodological and scientific advice to manufacturers of medicinal products be further optimised at European level ...
Posted by Michael Wonder on 02 Sep 2020
Talazoparib in breast cancer: hint of considerable added benefit
1 September 2020 - Advantages in health related quality of life, symptoms and side effects outweigh disadvantages. ...
Posted by Michael Wonder on 17 Aug 2020
Castration-resistant prostate cancer with a high risk of metastasis: enzalutamide has an additional benefit
17 August 2020 - New data from the PROSPER study shows benefit in overall survival. ...
Posted by Michael Wonder on 13 Aug 2020
Predictors of negotiated prices for new drugs in Germany
13 August 2020 - In Germany, all new, innovative medicines are subject to an early benefit assessment by the German Federal ...
Posted by Michael Wonder on 06 Aug 2020
Darolutamide in prostate cancer: indication of considerable added benefit
3 August 2020 - Advantages in overall survival, symptoms and health-related quality of life. ...